Anti-cxcr4 antibodies and antibody-drug conjugates
AssigneePfizer Inc.
InventorsShu-Hui LIU, Flavia Mercer PERNASETTI, Weihsien HO
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
Claims6
1-39. (canceled)
An isolated polynucleotide comprising a nucleotide sequence encoding an antibody, or an antigen binding fragment thereof, that binds to chemokine receptor 4 (CXCR4) and comprises:
- a) a heavy chain variable (VH) region comprising (i) a VH CDR1 comprising SEQ ID NO:107, 113, or 114;
- (ii) a VH CDR2 comprising SEQ ID NO:
- 162 or 128;
- and (iii) a VH CDR3 comprising SEQ ID NO:
- 112;
- and;
- b) a light chain variable region (VL) region comprising (i) a VL CDR1 comprising SEQ ID NO:
- 144;
- (ii) a VL CDR2 comprising 145;
- and (iii) a VL CDR3 comprising SEQ ID NO:
- 139.
44-54. (canceled)
Dependencies are inferred from the claim text.